Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

- Phase 1b Combination Data Highlight Favorable Tolerability and Additive Antiviral Activity of HCV-796 -

EXTON, Pa., April 13, 2007 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced additional data from a Phase 1b study of HCV- 796, a unique, orally dosed hepatitis C virus (HCV) polymerase inhibitor at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). This meeting is being held in Barcelona, Spain. These data on the antiviral activity and tolerability of twice daily HCV-796 in combination with pegylated interferon alfa-2b (peg-IFN) elaborate on previously presented data. HCV-796 is currently undergoing Phase 2 evaluation and is being co-developed with Wyeth Pharmaceuticals, a division of Wyeth .

These Phase 1b combination data demonstrate the additive antiviral effects of HCV-796 across multiple genotypes of hepatitis C virus, in treatment-naïve adult subjects with chronic hepatitis C infection. HCV-796 dosed twice daily plus peg-IFN displays clinical antiviral activity that is greater than that of HCV-796 or peg-IFN alone across all dose cohorts and tested HCV genotypes. Final safety and tolerability data show that HCV-796 is generally well tolerated when added to peg-IFN. Adverse events were generally consistent with known effects of interferons. No dose-limiting toxicities were observed across the range of HCV-796 study doses.

"In this Phase 1b study, HCV-796 provided added antiviral activity to that of pegylated interferon across multiple HCV genotypes and did so largely without altering interferon's tolerability profile," commented Colin Broom, ViroPharma's chief scientific officer. "The adverse events observed in patients on combination therapy were typical of those seen in patients on pegylated interferon alone. The antiviral activity of HCV-796, its strong tolerability profile, and its lack of dose limiting toxicities encou
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/17/2014)... , Sept. 17, 2014 An analysis ... regarding patients taking Sovaldi® (sofosbuvir), a new and expensive ... shows that over the last several months (May through ... downward trend in Sovaldi utilization. This suggests another surge ... new therapeutic regimens of similar efficacy and shorter duration ...
(Date:9/17/2014)... Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... its public offering of 4,500,000 shares of its common stock ... per share. Aratana has granted the underwriters a ... 675,000 shares of its common stock. ...
(Date:9/17/2014)... , Sept. 17, 2014 Sutro Biopharma, a ... and the biopharmaceutical division of Merck KGaA, Darmstadt, ... in the United States and ... and license agreement to develop antibody drug conjugates (ADCs). ... cytotoxic drug. The antibody is thought to specifically target ...
Breaking Medicine Technology:CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4
... Dehaier Medical Systems Ltd. (NASDAQ: ... in the development, assembly, marketing and sale of medical ... Company,s growing business earned a BBB+ Credit Rating from the ... and was approved as a member of the association. ...
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ) ("ShangPharma" ... research and development outsourcing company, today announced that it ... quarter and full year ended December 31, 2011 on ... to discuss the results at 08:00AM New York Time ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/17/2014)... September 17, 2014 Representatives with Capitol ... sponsor of Thursday’s Anti-Defamation League Event at the Four Seasons ... we consider it an honor to be a sponsor for ... Pain Institute. , Schocket went on to explain that the ... 600 community leaders and members at the Four Seasons to ...
(Date:9/17/2014)... Texas (PRWEB) September 17, 2014 ... provides key market data on the North America ... millions of US dollars, volume (in units) and ... –, Female Sterilization Devices ... (Tubal Clips and Rings)) , Endometrial ...
(Date:9/17/2014)... Kamut International is pleased to announce that ... Michael Angelo’s new “Made With Organic” ready-made, frozen meals ... ready made, frozen meal. Michael Angelo’s products feature KAMUT® ... products align well with Kamut International’s mission to support ... must be grown certified organic. , The new “Made ...
(Date:9/17/2014)... 17, 2014 Promising new research published ... more light on the potential ability of ketones to ... dementia. The study shows that brain ... caused by impaired glucose uptake and/or utilization, and results ... function. , The study, by the Research Center on ...
(Date:9/17/2014)... Right now no one can say whether yoga provides ... a new article in the Journal of Psychiatric ... scores of people with the condition who practice yoga. ... be a substantial help, but it sometimes carries risks, ... yoga for bipolar disorder," said lead author Lisa Uebelacker, ...
Breaking Medicine News(10 mins):Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 3Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 4Health News:KAMUT® Brand Wheat Delivers a High Quality Ingredient and Authentic Italian Taste for Michael Angelo’s New Ready-Made Meals featuring Organic Ingredients 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 3Health News:Survey finds benefits, risks of yoga for bipolar disorder 2Health News:Survey finds benefits, risks of yoga for bipolar disorder 3
... Point Action Plan on infectious waste control during a ... Monday,s Washington Times (link below), Emergency Preparedness ... issues, such as SARS, have highlighted the vulnerability our ... the area of operational sustainability in a crisis. ...
... visits to doctors and hospitals by people with the disease ... are still reporting new cases of infection with the H1N1 ... in visits to doctors and hospitals by people with the ... health official said Thursday. , "At the national level, ...
... Congress Urged to Support Bill for Bone Health Promotion ... (NOF) in conjunction with the National Coalition for Osteoporosis ... Hill today to engage Congress in an action plan ... lawmakers to sign on to the "Bone Health Promotion ...
... early were more likely to have been victims , , ... when they started menstruating, the more likely black women ... report. , The finding suggests childhood sexual abuse may ... at more than 35,000 women, aged 21 to 69, ...
... Link Services, CaseworkersPHILADELPHIA, May 21 The Field ... the University of Pennsylvania has announced ... Change, Microsoft Corp. and Motorola to pilot the ... private entities, this groundbreaking interoperable, real-time technology system ...
... 2009 Issue Examines Experiences of Denton ... Center DALLAS, May 21 T-System, Inc., the ... departments and urgent care centers, today announced that its Emergency ... in a column entitled "ED Information Systems: A Guideline For ...
Cached Medicine News:Health News:Coalition Calls on Secretary of Health to Make Hospital Emergency Preparedness a Priority 2Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 2Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 3Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 4Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 5Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 6Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 7Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 8Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 9Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 10Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 11Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 12Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 13Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 2Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 3Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 4Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 5Health News:Childhood Sexual Abuse Might Spur Early Periods 2Health News:University of Pennsylvania, Montgomery County Partner on Integrated, Interoperable System Design for Child Welfare 2Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 2Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 3
Touch-Trol Suction Catheter Mini-Tray...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Suction Catheter Kits with Sterile Saline (Bottle)...
Our suction kits include a Tri-Flo® suction catheter, a pop-up solution basin and two sturdy, precuffed latex exam gloves in an inner wallet. Infant and pediatric kits (5/6, 8 and 10 Fr) feature ...
Medicine Products: